Harvard Bioscience (HBIO) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
- Qualcomm shares fall on Intel warning and legal concerns
- Marvell Technology shares drop on Lumentum deal concerns
- Oracle shares drop on AI spending concerns and Microsoft criticism
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- SpaceX stock drops on launch setback and sector selloff
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Harvard Bioscience Announces First Quarter 2022 Financial Results
May 4, 2022 7:00 AM EDTÂ Revenue up 7% year-over-year despite volatility in China related to COVID-19 and global supply chain headwinds
HOLLISTON, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the Company) today announced financial results for the first quarter ended March 31, 2022.
Jim Green, Chairman and CEO, said, Our revenue was up 7% on strength from North American sales... More



